OR WAIT 15 SECS
A new consortium involving Arecor, FUJIFILM Diosynth Biotechnologies and the Center for Process Innovation will focus on formulation innovation as a way to improve downstream processing and reduce biopharmaceutical cost.
Improved formulation and higher downstream yield and product quality are driving a new consortium involving Arecor, the Center for Process Innovation (CPI), and Fujifilm Diosynth Biotechnologies. The two-year project, called "Improved Downstream Operation Through Formulation Innovation," is supported by a government grant from Innovate UK as part of its $30.4-million industrial biotechnology catalyst program.
The project's goal is to achieve a step change in biopharmaceutical yield and quality by improving product stability during downstream processing. Arecor will contribute its formulation expertise and stabilization platform, while its partners will provide bioprocessing expertise and predictive modeling know-how. The partners expect to deliver a new biopharmaceutical formulation platform that can be applied to routine downstream biopharmaceutical manufacturing processes, with the goal of reducing biopharmaceutical production costs, and, ultimately the cost of therapeutics to healthcare providers.
Source: Cambridge Network